Keryx Biopharmaceuticals, Inc. today announced results from a 48-week Open Label Extension safety study in which Ferric Citrate demonstrated long-term safety and efficacy in dialysis-dependent chronic kidney disease patients with elevated serum phosphorus levels, or hyperphosphatemia. The OLE findings were presented as a late-breaking poster at the 2014 American Society of Nephrology's Kidney Week meeting in Philadelphia, PA.